MX2022016281A - Composiciones y metodos antivirales de amplio espectro. - Google Patents

Composiciones y metodos antivirales de amplio espectro.

Info

Publication number
MX2022016281A
MX2022016281A MX2022016281A MX2022016281A MX2022016281A MX 2022016281 A MX2022016281 A MX 2022016281A MX 2022016281 A MX2022016281 A MX 2022016281A MX 2022016281 A MX2022016281 A MX 2022016281A MX 2022016281 A MX2022016281 A MX 2022016281A
Authority
MX
Mexico
Prior art keywords
methods
broad spectrum
spectrum antiviral
antiviral compositions
presented
Prior art date
Application number
MX2022016281A
Other languages
English (en)
Inventor
Frank Kayser
Stacy Remiszewski
Qun Sun
Lillian W Chiang
Eain Anthony Murphy
Sarah Jocelyn Fink
Original Assignee
Evrys Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evrys Bio Llc filed Critical Evrys Bio Llc
Publication of MX2022016281A publication Critical patent/MX2022016281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se presentan nuevos compuestos que contienen tiazol e isoquinolina que son útiles para tratar y/o prevenir infecciones virales de amplio espectro. También se presentan métodos para tratar y/o prevenir infecciones virales de amplio espectro. Estos compuestos han mostrado inhibición de la replicación de HCMV, virus de la influenza, virus Zika, virus BK y RSV en ensayos a base de células.
MX2022016281A 2017-10-18 2020-07-13 Composiciones y metodos antivirales de amplio espectro. MX2022016281A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762574067P 2017-10-18 2017-10-18

Publications (1)

Publication Number Publication Date
MX2022016281A true MX2022016281A (es) 2023-02-09

Family

ID=66173872

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004475A MX2020004475A (es) 2017-10-18 2018-10-17 Composiciones y metodos antivirales de amplio espectro.
MX2022016281A MX2022016281A (es) 2017-10-18 2020-07-13 Composiciones y metodos antivirales de amplio espectro.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004475A MX2020004475A (es) 2017-10-18 2018-10-17 Composiciones y metodos antivirales de amplio espectro.

Country Status (11)

Country Link
US (2) US11459321B2 (es)
EP (1) EP3697783A4 (es)
JP (2) JP7342010B2 (es)
KR (1) KR20200060772A (es)
CN (1) CN111819175A (es)
AU (2) AU2018350999B2 (es)
BR (1) BR112020007879A2 (es)
CA (1) CA3079396A1 (es)
IL (1) IL273990B1 (es)
MX (2) MX2020004475A (es)
WO (1) WO2019079519A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005939A1 (en) 2016-07-01 2018-01-04 The Board Of Regents Of The University Of Texas System Methods, apparatuses, and systems for creating 3-dimensional representations exhibiting geometric and surface characteristics of brain lesions
EP4271675A1 (en) * 2020-12-31 2023-11-08 Evrys Bio, LLC Anti-tumor compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
EP2125778A1 (en) 2006-12-22 2009-12-02 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
US20150335657A1 (en) * 2014-05-05 2015-11-26 The Trustees Of Princeton University Methods for Modulating Sirtuin Enzymes
WO2016027879A1 (ja) * 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016077240A2 (en) 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
AU2015346657B9 (en) * 2014-11-10 2020-01-16 Evrys Bio, Llc Anti-HCMV compositions and methods
WO2016107832A1 (en) * 2014-12-30 2016-07-07 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
WO2016177655A1 (en) * 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections

Also Published As

Publication number Publication date
JP2021500401A (ja) 2021-01-07
KR20200060772A (ko) 2020-06-01
JP7342010B2 (ja) 2023-09-11
JP2023162363A (ja) 2023-11-08
EP3697783A4 (en) 2023-04-26
IL273990A (en) 2020-05-31
RU2020114888A3 (es) 2021-11-18
AU2018350999B2 (en) 2022-09-08
CA3079396A1 (en) 2019-04-25
CN111819175A (zh) 2020-10-23
EP3697783A1 (en) 2020-08-26
US11459321B2 (en) 2022-10-04
IL273990B1 (en) 2024-07-01
WO2019079519A1 (en) 2019-04-25
RU2020114888A (ru) 2021-11-18
AU2022256094B2 (en) 2023-07-20
BR112020007879A2 (pt) 2020-10-13
AU2022256094A1 (en) 2022-11-17
US20210139475A1 (en) 2021-05-13
US20230416241A1 (en) 2023-12-28
AU2018350999A1 (en) 2020-05-07
MX2020004475A (es) 2020-10-28

Similar Documents

Publication Publication Date Title
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
MX2020006864A (es) Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
PH12017501534A1 (en) Antiviral compounds
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
PH12017501958A1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
MX2016009828A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b.
PH12020550525A1 (en) Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv)
MX2017014550A (es) Inhibidores del antigeno nuclear epstein-barr 1 (ebna1) y metodos que los utilizan.
GEP20237457B (en) Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
PH12019550069A1 (en) Nucleoside phosphate compound and preparation method and use thereof
MX2022016281A (es) Composiciones y metodos antivirales de amplio espectro.
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
WO2017021471A8 (en) Methods for amplifying and sequencing the genome of a hepatitis c virus
WO2016119052A8 (en) Compositions and methods for enhancing oncolytic virus efficacy
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.
CL2021002307A1 (es) Uso de virus oncolíticos para el tratamiento del cáncer
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds